

The GOG Highlight Reel – Educational Series
Fall 2023
November 30, 2023

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	DISCLOSURE <company & role>
Planning Disclosures			
Thomas Herzog, MD	Moderator		Astra Zeneca; Caris; Clovis; Eisai; Epsilon; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics: Scientific Advisory Boards
Bradley J. Monk, MD	Moderator		Honoraria: Consulting/Speaker: Agenus, Akeso, AstraZeneca, Aravive, Clovis, Eisai, Elevar, Genmab/Seattle Genetics, GOG Foundation. Gradalis, Iovance, Karyopharm, Merck, McKesson, Mersana, Myriad, Novocure, Pfizer, Roche/Genentech, Sorrento, Tesaro/GSK, VBL
Speaker Disclosures			
Robert Coleman, MD	Speaker		Agenus; Alkermes, Inc.; AstraZeneca; Clovis Oncology, Inc.; Deciphera Pharmaceuticals Inc. ; EISAI INC. ; Genentech USA, Inc.; GlaxoSmithKline; Gradalis: Mersana; Novocure Inc.; oncxerna; Regeneron Pharmaceuticals: Consultant AbbVie; Immunogen; Janssen Biotech, Inc.; Merck; Novartis; Onxeo; Seagen Inc.: Grant / Contract Vbl: Data And Safety Monitoring
Thomas Herzog, MD	Speaker		Astra Zeneca; Caris; Clovis; Eisai; Epsilon; Genentech; GSK; J&J; Merck; Mersana; Novocure; Seattle Genetics: Scientific Advisory Boards
Bhavana Pothuri, MD	Speaker		AstraZeneca; Celisio; Immunogen; Merck; Mersana; Seattle Genetics; Sutro; Takada; Tesaro; Clovis Oncology: Research funding support/ Ad Board fees: Eisai, Lily, GOG Foundation: Advisory Board
Leslie Randall, MD	Speaker		AstraZeneca Pharmaceuticals LP; Clovis Oncology, Inc.; GlaxoSmithKline; Immunogen; Seagen Inc.: Consultant

FACULTY DISCLOSURE INFORMATION

Ritu Salani, MD, MBA	Speaker		Merck ; Eisai; GSK; Seagen; Regeneron; Karyopharm; Immunogen: Ad board/Consultant Up To Date; Elsevier: Writer
Angeles Alvarez Secord, MD, MHSc	Speaker		AbbVie; Aravive; AstraZeneca; Clovis Oncology, Inc.; Eisai; Genentech; GSK; Merck; National Cancer Trial Network; Oncoquest; Seagen Inc; Tapimmune; VBL Therapeutics: Grant / Contract Immunogen; Myriad Genetic Laboratories, Inc.: Consultant AAOGF; GOG Foundation; SGO: Other
Brian Slomovitz, MD	Speaker		Abbvie; AstraZeneca; Clovis; GSK; Genentech; Merck; Myriad: Consultant
Michelle N Small, MPH	Staff	X	
Jill Reese	Staff	X	